SYRE
HOLD / NEUTRALNeutralComposite
46.30
Technical
90.50
Fundamental
16.70
Rank
—
Price
104.94
Hurst
0.46
As of
Aug 5, 2026
Daily
Spyre Therapeutics, Inc.
HealthcareBiotechnologySpyre Therapeutics is a clinical-stage biotech company developing antibody-based medicines for inflammatory bowel disease and rheumatic conditions. Its pipeline includes several monoclonal antibodies targeting specific immune pathways—such as SPY001 (in phase 2 for IBD), SPY002 and SPY072 (targeting TL1A), and SPY003 (targeting IL-23)—as well as combination therapies designed to address multiple disease mechanisms simultaneously. The company was incorporated in 2013 and is headquartered in Waltham, Massachusetts.
Market cap
$9.0B
P/E (trailing)
—
P/E (forward)
-27.55
PEG ratio
—
Dividend yield
0.00%
Beta
3.11
52w range
21.15 – 110.18
Return on equity
-22.98%
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 96.56 (+294.8%) · range 22.18–108.92
Cycle position
78/ 100 cycle scoreEXIT ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 4 · NOT READY · exit proximity 23
Conviction
6/ 100 · maturity 0%
Buildup.331
EMA entry setup.424
Fundamentals.2517
Volume profile
POC
90.61
Price vs POC
+6.6%
Overhead supply
22%
Runway
open sky
Value area 81.05–101.98 · 22% of 120d volume overhead · moderate overhead
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -16.58% | +4.38% | mature |
| 40d | -13.82% | +4.38% | mature |